{"organizations": [], "uuid": "2e302204c65ca424b81ebd50749bfc9eb0d96413", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180326.html", "section_title": "Archive News &amp; Video for Monday, 26 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-1nkemia-says-unit-leanbio-sets-up/brief-1nkemia-says-unit-leanbio-sets-up-jv-with-reig-jofre-idUSFWN1R80WQ", "country": "US", "domain_rank": 408, "title": "BRIEF-1nKemia Says Unit Leanbio Sets Up JV With Reig Jofre", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.331, "site_type": "news", "published": "2018-03-26T23:21:00.000+03:00", "replies_count": 0, "uuid": "2e302204c65ca424b81ebd50749bfc9eb0d96413"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-1nkemia-says-unit-leanbio-sets-up/brief-1nkemia-says-unit-leanbio-sets-up-jv-with-reig-jofre-idUSFWN1R80WQ", "ord_in_thread": 0, "title": "BRIEF-1nKemia Says Unit Leanbio Sets Up JV With Reig Jofre", "locations": [], "entities": {"persons": [{"name": "reig jofre", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-1nkemia says unit leanbio", "sentiment": "negative"}, {"name": "leanbio", "sentiment": "none"}, {"name": "syna therapeutics", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26 (Reuters) - 1NKEMIA IUCT GROUP SA:\n* SAYS UNIT LEANBIO AND REIG JOFRE SET UP JOINT VENTURE SYNA THERAPEUTICS TO DEVELOP BIOPHARMACEUTICAL PRODUCTS\n* SAYS LEANBIO TO HOLD 50 PERCENT IN JV * SAYS FOUNDING PARTNERS WILL CONTRIBUTE CAPITAL OF 9 MILLION EUROS TILL PHASE III OF CLINICAL DEVELOPMENT\nSource text: bit.ly/2ISWFyr\nFurther company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://bit.ly/2ISWFyr", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-26T23:21:00.000+03:00", "crawled": "2018-03-27T11:58:37.000+03:00", "highlightTitle": ""}